Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.37 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444029 | 0.98 | AOC3 (0.42) | AOC3DPP4F2CTSDALOX15 | |
| SCHEMBL9268820 | 0.79 | SMN1; SMN2 (0.37) | DPP4F2ALOX15CYP3A4TSHR | |
| SCHEMBL9416672 | 0.76 | SMN1; SMN2 (0.35) | DPP4F2ALOX15CYP3A4TSHR | |
| SCHEMBL897649 | 0.76 | KDM4E (0.38) | DPP4F2ALOX15CYP3A4TSHR | |
| SCHEMBL9631211 | 0.76 | ALDH1A1 (0.39) | DPP4F2ALOX15CYP3A4TSHR | |
| SCHEMBL2028407 | 0.76 | ALDH1A1 (0.46) | ALOX15CYP3A4TSHRHTR2ATAAR1 | |
| Ammonia Solution, Strong SCHEMBL27951261 | 0.76 | HDAC1 (0.39) | ALOX15CYP3A4TSHRSMN1; SMN2KDM4E | |
| SCHEMBL9631266 | 0.76 | CYP3A4 (0.35) | DPP4F2ALOX15CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL26908778 | 0.75 | TAAR1 (0.38) | AOC3ALOX15CYP3A4TSHRHTR2A | |
| Hydrochloric Acid SCHEMBL9769539 | 0.75 | CYP3A4 (0.42) | ALOX15CYP3A4TSHRHTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20190076406-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-03-14 | — | — | US | disclosed |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180000791-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2018-01-04 | — | — | US | disclosed |
| US-20160279104-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-09-29 | — | — | US | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-8906642-B2 | Methods and compositions for the treatment and diagnosis of haemorrhagic conversion | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2014-12-09 | — | — | US | disclosed |
| US-20140170160-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2014-06-19 | — | — | US | disclosed |
| US-8636995-B2 | Methods and devices to regulate stem cell homing | CARDIAC PACEMAKERS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120276111-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-11-01 | — | — | US | disclosed |
| US-20120014939-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF HAEMORRHAGIC CONVERSION | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2012-01-19 | — | — | US | disclosed |
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-07-02 | — | — | US | disclosed |
| WO-2009061830-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20080057027-A1 | METHODS AND DEVICES TO REGULATE STEM CELL HOMING | CARDIAC PACEMAKERS, INC (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058922-A1 | METHODS AND DEVICES EMPLOYING VAP-1 INHIBITORS | CARDIAC PACEMAKERS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2006094201-A2 | SEMICARBAZIDE-SENSITIVE AMIDE OXIDASE INHIBITORS | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1663954-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL CO. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096360-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICALS COMPANY | 2005-05-05 | — | — | US | disclosed |
| WO-2005014530-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL CO. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170160-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | DPP4 3843/4885HTR2A 4841/4885AOC3 348/4885 |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | DPP4 3036/4885HTR2A 4301/4885AOC3 55/4885 |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | DPP4 3036/4885HTR2A 4301/4885AOC3 55/4885 |
| US-20160279104-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | DPP4 3843/4885HTR2A 4841/4885AOC3 348/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | DPP4 519/4885HTR2A 4664/4885AOC3 24/4885 |
| US-20120276111-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | DPP4 3843/4885HTR2A 4841/4885AOC3 348/4885 |
| US-20190076406-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | DPP4 3843/4885HTR2A 4841/4885AOC3 348/4885 |
| US-20050096360-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC3 | DPP4 3116/4885HTR2A 1662/4885AOC3 3/4885 |
| US-20180000791-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR | VCAM1, VAPB, VAPA | DPP4 3843/4885HTR2A 4841/4885AOC3 348/4885 |
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | VCAM1, VAPB, FLT1 | DPP4 3769/4885HTR2A 4812/4885AOC3 402/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | DPP4 438/4885HTR2A 4703/4885AOC3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.